Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ravulizumab versus placebo for HSCT-associated thrombotic microangiopathy
NL-OMON54406Phase 3Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ravulizumab in transplant-associated thrombotic microangiopathy (TA-TMA) (3 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: TMA response throughout 26 weeks. Started Jun 2022; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)
Beyond the preview
Go deeper on NL-OMON54406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54406.